1. Health technology

  2. •

    Pharmaceuticals: major
Bachem Holding AG

Bachem Holding AG

OOTC:BCHMY
10.21
USD
+0.12
(+1.19%)
7.58BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.25
0.27
0.31
0.35
0.39
0.42
0.45
0.58
0.71
0.72
0.78
0.81
0.93
- -
Basic EPS, GAAP
0.04
0.04
0.05
0.06
0.06
0.07
0.08
0.11
0.16
0.14
0.15
0.16
0.2
- -
Free Cash Flow per Basic Share
0.06
0.05
0.05
-0.02
-0.02
-0.02
0.05
0.07
-0.03
-0.07
-0.02
-0.19
-0.08
- -
Dividend per Share
0.03
0.04
0.03
0.03
0.04
0.04
0.04
0.06
0.03
0.07
0.08
0.08
0.04
- -
Book Value per Share
0.5
0.52
0.52
0.54
0.55
0.57
0.64
0.68
1.53
1.59
1.77
1.86
1.95
1.93
Tangible Book Value per Share
0.49
0.51
0.51
0.53
0.53
0.55
0.62
0.66
1.51
1.57
1.75
1.83
1.91
1.89
Basic Weighted Avg Shares
673
674
675
675
677
677
690
698
706
735
745
747
747
749
Sales/Revenue/Turnover
171
184
209
236
262
283
314
402
503
532
577
605
695
- -
Operating Margin (%)
17.25
18
18.45
19.05
18.68
19.4
19.88
24.05
25.62
23.93
22.41
21.98
24.07
- -
Depreciation Expense
18
19
18
20
21
23
25
26
28
33
37
43
47
- -
Net Income, GAAP
24
29
32
41
42
47
54
78
115
101
112
120
149
- -
Effective Tax Rate (%)
18.32
20.03
14.59
10.2
13.64
14.63
10.28
14.18
12.71
10.16
9.94
11.07
4.86
- -
Profit Margin (%)
13.83
15.8
15.26
17.42
15.97
16.51
17.27
19.42
22.79
18.93
19.38
19.87
21.41
- -
Working Capital
148
161
148
126
115
111
227
215
699
596
677
542
321
312
LT Debt
- -
- -
- -
- -
- -
- -
60
- -
- -
- -
- -
- -
- -
- -
Total Equity
336
349
353
365
374
384
448
476
1,121
1,170
1,321
1,391
1,458
1,444
Return on Invested Capital (%)
6.19
7.5
8.69
9.98
9.68
9.28
10.23
16.01
13.86
9.84
9.27
8.65
11.08
- -
Return on Capital (%)
6.26
7.79
8.62
10.46
9.45
9.37
10.01
15.21
14.22
8.71
8.98
8.87
10.47
- -
Return on Common Equity (%)
7.05
8.48
9.06
11.47
11.3
12.3
13.02
16.91
14.36
8.79
8.98
8.87
10.44
- -

Capital Structure

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
747
747
747
Market Capitalization
4,153
4,263
6,125

Working Capital

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
711
727
829
Cash, Cash Equivalents & STI
29
31
52
Accounts Receivable, Net
174
179
174
Inventories
483
494
577
Total Current Liabilities
292
405
517
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.43%
32.61%
4.83%
Free Cash Flow
9.05%
108.21%
-58.19%
Net Income, GAAP
17.97%
15.41%
23.74%
Sales/Revenue/Turnover
13.03%
11.82%
14.84%
Total Cash Common Dividend
17.22%
13.51%
-48.77%

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
605
2025
- -
- -
- -
- -
695
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.16
2025
- -
- -
- -
- -
0.2
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.08
2025
- -
- -
- -
- -
0.04
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
Address
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business